Scarica l'app Stockscreener
8.89
18.93%
1.415
Dopo l'orario di chiusura:
8.96
0.07
+0.79%
Precedente Chiudi:
$7.475
Aprire:
$7.252
Volume 24 ore:
7.28M
Relative Volume:
3.69
Capitalizzazione di mercato:
$995.75M
Reddito:
-
Utile/perdita netta:
$-129.47M
Rapporto P/E:
-5.8695
EPS:
-1.5146
Flusso di cassa netto:
$-114.08M
1 W Prestazione:
-28.19%
1M Prestazione:
-35.95%
6M Prestazione:
-21.47%
1 anno Prestazione:
+53.81%
Intervallo 1D:
$7.23
$8.97
Intervallo di 1 settimana:
$7.23
$13.04
Portata 52W:
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Nome
Oric Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 388-5600
Indirizzo
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
8.89 | 995.75M | 0 | -129.47M | -114.08M | -1.5146 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-11-20 | Iniziato | Evercore ISI | Outperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-10-31 | Iniziato | Wells Fargo | Overweight |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-02-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Iniziato | Wedbush | Outperform |
| 2023-03-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Perform |
| 2022-04-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-03-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-13 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Citigroup | Neutral |
| 2020-05-19 | Iniziato | Guggenheim | Buy |
| 2020-05-19 | Iniziato | JP Morgan | Overweight |
| 2020-05-19 | Iniziato | Jefferies | Buy |
Mostra tutto
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN
ORIC Pharma drops after early-stage trial data for prostate cancer therapy - MSN
ORIC Pharmaceuticals (ORIC) Is Down 28.2% After Selecting 400 mg Rinzimetostat Dose for Phase 3 - Sahm
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Sahm
ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history - Yahoo Finance Australia
ORIC Pharmaceuticals stock nosedives 25% after hours: What is going on? - MSN
ORIC Pharmaceuticals Reports Inducement Grants - National Today
ORIC gives new employee 80,000 stock options and 15,000 RSUs - Stock Titan
ORIC Pharmaceuticals’ Global Ambitions amid Tumultuous Share Movements - StocksToTrade
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 11.6% HigherTime to Buy? - MarketBeat
ORIC Pharmaceuticals Faces Turbulence Amid Prostate Cancer Drug Advancements - timothysykes.com
Investors Purchase Large Volume of Oric Pharmaceuticals Call Options (NASDAQ:ORIC) - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC) - The Globe and Mail
Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI - The Globe and Mail
HC Wainwright Reiterates Buy Rating for ORIC, Maintains Price Ta - GuruFocus
HC Wainwright Reaffirms Buy Rating for Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Oric Pharmaceuticals stock falls on prostate cancer trial data, Sellside Comments - Investing.com Canada
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock - Investing.com
Guggenheim Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC) - The Globe and Mail
HC Wainwright Reiterates Buy Rating for ORIC, Maintains Price Target | ORIC Stock News - GuruFocus
ORIC Stock Pullback Seen as Buying Opportunity - GuruFocus
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3 - Yahoo Finance
What's Behind The Drop In Oric Pharmaceuticals Stock Today? - Sahm
What's behind the drop in Oric Pharmaceuticals stock today? - MSN
ORIC: Opportunity Arises in Oric Pharmaceuticals Amid Price Drop - GuruFocus
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
Wolfe Research reiterates Peerperform on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
Pfizer (PFE) Competes in Prostate Cancer Treatment Landscape - GuruFocus
ORIC Pharmaceuticals: Updates Did Not Bode Well For This Valuation (NASDAQ:ORIC) - Seeking Alpha
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Oric Pharma Unveils Rinzimetostat Phase Ib Data And Outlines Phase III Study In Prostate Cancer - RTTNews
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down Following Analyst Downgrade - MarketBeat
Oric Pharmaceuticals (ORIC) Sees Overreaction to Phase 1 Study D - GuruFocus
Oric Pharmaceuticals (NASDAQ:ORIC) Given New $17.00 Price Target at Wedbush - MarketBeat
Wedbush Lowers Price Target for ORIC Pharmaceuticals | ORIC Stoc - GuruFocus
Cantor Fitzgerald reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com
Beyond Meat Posts Downbeat Q4 Results, Joins RH, ORIC Pharmaceuticals And Other Big Stocks Moving Lower I - Benzinga
ORIC falls after hours on safety concerns around prostate cancer candidate at higher doses - MSN
ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On? - Benzinga
24H｜DEFT Soared 50%; NCino Surged 20%; Oric Pharmaceuticals Plunged 25%; Battalion Oil Down 9% - Tiger Brokers
Oric Advances Rinzimetostat Toward First Prostate Cancer Phase 3 - TipRanks
Transcript : ORIC Pharmaceuticals, Inc.Special Call - marketscreener.com
ORIC Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile - bitget.com
ORIC's Rinzimetostat Shows Promise in Prostate Cancer Treatment - GuruFocus
Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial - MarketBeat
Oric Pharmaceuticals Inc Azioni (ORIC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Oric Pharmaceuticals Inc Azioni (ORIC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Feb 24 '26 |
Sale |
13.51 |
52,000 |
702,686 |
68,148 |
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):